On May 19, 2026 Myosin Therapeutics, a clinical stage biotechnology company developing innovative therapies for oncology, reported that the first patient has been dosed in its Phase 1/2 STAR-GBM study. The trial is designed to assess safety, tolerability, pharmacokinetics, and preliminary signals of clinical activity with longitudinal imaging in adults with newly diagnosed glioblastoma (GBM). With support from the National Cancer Institute (NCI/NIH), the trial is being conducted in collaboration with the Mayo Clinic across its Minnesota, Florida, and Arizona campuses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MT-125 is a first-in-class inhibitor of non-muscle myosin II (NMII), designed to disrupt the physical mechanics of tumor cells to induce tumor cell collapse and death through non-redundant mechanisms distinct from any existing therapy.

"This marks the transition of MT-125 from a strong mechanistic and preclinical foundation into clinical testing in patients with one of the most aggressive cancers," said Courtney Miller, PhD, Chief Executive Officer of Myosin Therapeutics. "Our research shows that targeting the mechanical dependencies of tumor cells represents a fundamentally different approach to cancer treatment, and this study is designed to test that hypothesis directly in patients with glioblastoma."

"MT-125 introduces a novel therapeutic strategy that is distinct from conventional cytotoxic and targeted approaches," said Karen Smith, MD, PhD, MBA, LLM, Chief Medical Officer of Myosin Therapeutics. "Partnering with Mayo Clinic allows us to efficiently evaluate both safety and early biological activity in a patient population with significant unmet need."

MT-125 has received Orphan Drug Designation for malignant gliomas and Fast Track Designation for glioblastoma, supporting an accelerated regulatory pathway. In addition to GBM, MT-125 is being developed for other treatment-resistant cancers, including acute myeloid leukemia and pancreatic cancer. Additional information on the STAR GBM study is available at clinicaltrials.gov (NCT07185880).

The STAR-GBM trial is supported by the National Cancer Institute and by a syndicate of life sciences investors and philanthropic organizations.

(Press release, Myosin Therapeutics, MAY 19, 2026, View Source [SID1234665877])

On May 19, 2026 Mestag Therapeutics, a clinical-stage biotech company harnessing fibroblast immunology for the benefit of patients with inflammatory disease and cancer, reported the dosing of the first patient in a Phase 1 clinical trial evaluating MST-0312 in patients with selected advanced solid tumors. The first in human trial, named the STARLYS trial, is an adaptive, modular multi-part, multi-arm open-label study designed to evaluate the safety, tolerability, pharmacodynamics, pharmacokinetics and anti-tumor activity of MST-0312 alone and in combination with pembrolizumab.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

MST-0312 is a bispecific antibody designed to activate lymphotoxin-beta receptor (LTBR) in the tumor microenvironment to induce the formation of tertiary lymphoid structures (TLS) and associated high endothelial venules (HEV) in tumor tissue. TLS are a hallmark of effective anti-tumor immunity consisting of aggregates of T, B and dendritic cells, associated with the recruitment, education, and activation of immune cells to drive anti-tumor immune responsesi,ii. Patients with TLS and HEV in their tumors show significantly improved response to treatment and extended survival outcomes compared to patients whose tumors lack these structuresiii,iv,v,vi. The STARLYS trial will initially evaluate MST-0312 in tumors formed in barrier organs (lung, gut, bladder, breast and skin), which are believed to be particularly sensitive to TLS formation.

"Dosing the first patient with MST-0312 is a significant milestone in developing this potential new therapeutic class," said Dr. Lindsey Rolfe, MBChB, Chief Medical Officer of Mestag. "Our carefully designed study evaluates monotherapy and combination therapy in immunologically ‘cold’ and ‘warm’ tumors, generating multiple mechanistic and clinical insights to inform future development. This important step reflects the scientific rigor and dedication of the Mestag team, as we advance novel therapies for patients."

Dr. Emiliano Calvo MD PhD, a Principal Investigator of the study and Director of Clinical Research at START Madrid-CIOCC (Centro Integral Oncológico Clara Campal) Hospital in Madrid, Spain where the first patient was dosed, said "MST-0312 is an exciting new investigative approach for the treatment of solid tumors and we are thrilled to have dosed the first patient in the STARLYS trial."

Dr. Elena Garralda MD PhD, Co-Director of the Clinical Research Program and Head of Early Drug Development at Vall d’Hebron Institute of Oncology in Barcelona, Spain, and coordinating Principal Investigator of the STARLYS trial, added, "Published data show that the presence of TLS is associated with significantly improved outcomes for patients. Despite recent therapeutic advances, many patients with solid tumors derive limited benefit from current therapies. MST-0312 is designed to address this unmet need by inducing TLS and reshaping anti-tumor immunity. I look forward to working with the STARLYS investigators to evaluate MST-0312 in the clinic."

(Press release, Mestag Therapeutics, MAY 19, 2026, View Source [SID1234665844])

On May 19, 2026 Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company"), a clinical-stage biotechnology company developing immunotherapies for cancer patients, reported that members of its executive team will participate in one-on-one investor meetings at the following conference:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Jefferies Global Healthcare Conference 2026
Dates: June 2–4, 2026
Location: New York, United States

(Press release, Innate Pharma, MAY 19, 2026, View Source [SID1234665860])

On May 19, 2026 Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune disease, solid tumors and hematological malignancies indications, reported that Dr. Bing Hou has been appointed Chief Scientific Officer, reporting directly to Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Dr. Hou’s appointment underscores Antengene’s commitment to strengthening its innovation-driven R&D model as a global biotech company. In this role, Dr. Hou will lead Antengene’s efforts across Drug Discovery, Translational Medicine, and Chemistry, Manufacturing and Controls (CMC), with a focus on deepening the Company’s research engine and building a pipeline of next-generation therapeutic candidates with transformational potential.

Since joining Antengene in 2019, Dr. Hou has been a key member of the Company’s scientific leadership team, and prior to this appointment, served as Vice President, Head of Discovery Science & Translational Medicine. During his tenure, he has built and led a high-caliber discovery organization, helped guide Antengene’s R&D initiatives, advanced internally discovered programs into clinical development, and played an important role in establishing newly developed proprietary platforms designed to support future innovation programs.

"We are very pleased to appoint Dr. Bing Hou as Chief Scientific Officer of Antengene," said Dr. Jay Mei, Founder, Chairman, and Chief Executive Officer of Antengene. "Dr. Hou has made significant contributions to shaping Antengene’s scientific strategy and strengthening our internal research capabilities. Under his leadership, Antengene has built and advanced AnTenGager, the Company’s proprietary T-cell engager (TCE) 2.0 platform with broad applicability across autoimmune diseases, solid tumors and hematological malignancies, as well as other novel programs and platform technologies that support our next-generation pipeline. The global license agreement Antengene entered into with UCB for ATG-201, a CD19 x CD3 TCE developed from the AnTenGager platform for B cell-related autoimmune diseases, further highlights the strategic value of Antengene’s proprietary discovery capabilities. As we enter our next stage of growth, we look forward to Dr. Hou’s continued leadership in expanding our innovative pipeline, and bringing forward transformative therapies for patients globally."

"I am honored and excited to step into the role of Chief Scientific Officer at Antengene," said Dr. Bing Hou, Chief Scientific Officer of Antengene. "Antengene is advancing a number of highly promising programs across oncology and autoimmune diseases, and I believe we are well positioned to build a next-generation pipeline grounded in rigorous biology, differentiated mechanisms and platform innovation. Looking ahead, we will continue to focus on programs with the potential to address significant unmet medical needs, including T cell engagers developed from our proprietary AnTenGager platform; ATG-125, a B7-H3 x PD-L1 bispecific antibody-drug conjugate (ADC) designed to combine ADC and immuno-oncology mechanisms; and ATG-207, a globally first-in-class αCD3-TGF-β bifunctional fusion protein for T cell-driven autoimmune diseases. I look forward to continuing to work closely with the Antengene team to translate our differentiated science and platform capabilities into a robust pipeline of innovative medicines."

Dr. Hou received his Ph.D. in Biomedicine from the University of Leeds in the United Kingdom. He has published multiple high-impact research papers as first author or corresponding author in leading journals including Nature, Science Advances, and Cancer Research. He has filed more than 40 patent applications for novel therapeutics. As an inventor and/or principal leader, he has advanced multiple first-in-class or best-in-class drug candidates into various stages of clinical development.

(Press release, Antengene, MAY 19, 2026, View Source [SID1234665878])

On May 19, 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) reported it will present new data from nine approved and investigational medicines across more than 15 indications at the 2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, held 29 May to 2 June in Chicago.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Roche’s ASCO (Free ASCO Whitepaper) data reflect our commitment to addressing those cancers that impose the highest burden on patients and society," said Levi Garraway, MD, PhD, Roche’s chief medical officer and head of Global Product Development. "In particular, our ASCO (Free ASCO Whitepaper) data highlight significant advances in breast cancer, including the latest results for giredestrant and our evolving approach to HER2-positive metastatic disease."

Redefining the standard of care in breast cancer
Roche’s ASCO (Free ASCO Whitepaper) 2026 focus is on giredestrant, an investigational, oral, selective oestrogen receptor degrader (SERD) being studied in early and advanced oestrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer.

This subtype accounts for approximately 70% of breast cancer cases, and the majority are diagnosed in the early stage.1,2 Data from three phase III trials demonstrate giredestrant’s potential as a future standard of care endocrine therapy across multiple disease stages:

lidERA Breast Cancer: Building on the transformational results shared in December 2025, which demonstrated a 30% reduction in the risk of invasive disease recurrence or death,3 new data will indicate whether the efficacy and safety of giredestrant remain consistent across pre- and post-menopausal patients with early breast cancer. The lidERA data have been submitted to the U.S. Food and Drug Administration (FDA).
persevERA Breast Cancer: Primary results investigating giredestrant in combination with palbociclib as a first-line therapy in locally advanced or metastatic cancer will be presented. These data will provide context following the announcement that while the study did not meet its primary endpoint, the giredestrant combination showed a numerical improvement in this distinct patient population, suggesting that giredestrant is active in the first-line setting.
evERA Breast Cancer: New post-progression treatment analyses will be shared exploring the sustained clinical benefit for people treated with giredestrant plus everolimus in the post-cyclin-dependent kinase 4/6 inhibitor setting. The U.S. FDA recently accepted the New Drug Application for giredestrant based on the positive evERA data.
Our ASCO (Free ASCO Whitepaper) data also highlight progress in HER2-positive breast cancer, an area Roche has led for over 30 years:

RG6596/ZN-A-1041 in HER2-positive breast cancer: Preliminary results from a phase Ic expansion trial will provide early information on the safety and efficacy of ZN-A-1041, a highly blood-brain barrier-permeable, HER2-selective tyrosine kinase inhibitor, in combination with other HER2-targeted therapies, for patients with pre-treated HER2-positive metastatic breast cancer. Designed for enhanced brain penetration, ZN-A-1041 may improve the ability to prevent and treat brain metastases, a major challenge in metastatic breast cancers.
Advancing precision medicine and novel combinations
Roche is also presenting data from its diverse pipeline targeting specific genetic drivers and difficult-to-treat cancers, including:

Divarasib in non-small cell lung cancer (NSCLC): Roche will present results from the Krascendo 170 phase Ib/II study evaluating the next-generation oral KRAS G12C inhibitor divarasib combined with pembrolizumab in treatment-naive patients with KRAS G12C+ advanced NSCLC. These data informed the phase III Krascendo 2 study, which investigates this combination as a first-line therapy regardless of PD-L1 status. Divarasib is currently being evaluated in three pivotal phase III studies as a monotherapy or in chemotherapy-free combinations.
Lunsumio (mosunetuzumab) plus Polivy (polatuzumab vedotin) in diffuse large B-cell lymphoma (DLBCL): Roche will present updated data from the phase III SUNMO trial to further establish the efficacy and safety of Lunsumio plus Polivy compared to chemotherapy (R-GemOx) particularly in second-line patients with relapsed/refractory DLBCL who are not eligible for transplant. This first combination of a bispecific antibody and antibody-drug conjugate could potentially provide patients who often face poor prognoses and significant treatment burdens with an effective, fixed-duration, chemotherapy-free regimen.

Overview of key presentations featuring Roche medicines and molecules:

Medicine or molecule Abstract title Abstract number/ presentation details
Breast cancer
Giredestrant Giredestrant (GIRE) + palbociclib (PALBO) vs letrozole (LET) + PALBO as first-line (1L) therapy in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer (ER+, HER2– LA/mBC): Primary analysis of the phase III persevERA Breast Cancer (BC) trial #LBA1006 oral

Breast Cancer — Metastatic

Tuesday 02 June 2026
11:45 – 11:57 AM CDT
Giredestrant Efficacy and safety of giredestrant (GIRE) in patients (pts) with estrogen receptor-positive, HER2-negative early breast cancer (ER+, HER2– eBC) in the phase III lidERA BC clinical trial: Results by menopausal status #502 oral

Breast Cancer —Local/Regional/Adjuvant

Saturday 30 May 2026
1:39 – 1:51 PM CDT
Giredestrant Post-progression treatment (tx) analyses of evERA Breast Cancer (BC): A phase III trial of giredestrant (GIRE) + everolimus (E) in patients (pts) with estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC) previously treated with a CDK4/6 inhibitor (i) #1016 rapid oral

Breast Cancer — Metastatic

Sunday 31 May 2026
12:00 – 12:06 PM CDT
RG6596/ ZN-A-1041 Safety and efficacy of ZN-A-1041, a highly blood–brain barrier (BBB)-permeable HER2 tyrosine kinase inhibitor (TKI), + trastuzumab deruxtecan (T-DXd) or pertuzumab-trastuzumab (PH) in HER2-positive metastatic breast cancer (HER2+ mBC): Phase Ic expansion results from the ZN-A-1041-101-US trial #1055 poster

Breast Cancer — Metastatic

Monday 01 June 2026
1:30 – 4:30 PM CDT
Itovebi (inavolisib) Outcomes by lobular (lob) histology status at initial diagnosis in patients (pts) in the INAVO120 phase 3 trial with PIK3CA-mutated (mut), hormone receptor-positive (HR+), HER2-negative (HER2–), endocrine-resistant advanced breast cancer (aBC) treated with inavolisib (INAVO)/placebo (PBO) + palbociclib (PALBO) + fulvestrant (FULV) #1079 poster

Breast Cancer — Metastatic

Monday 01 June 2026
1:30 – 4:30 PM CDT
Kadcyla (trastuzumab emtansine) Adjuvant antibody–drug conjugate (ADC) eligibility and corresponding prognosis in HER2+ early breast cancer (eBC): A US-based real-world comparison of KATHERINE and DESTINY-Breast05 populations #535 poster

Breast Cancer —Local/Regional/Adjuvant

Monday 01 June 2026
1:30 – 4:30 PM CDT
Blood cancer
Lunsumio (mosunetuzumab) and Polivy (polatuzumab vedotin) Mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) versus rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL): Updated efficacy and safety from the phase 3 SUNMO study including in second-line (2L) versus third-line plus (3L+) patient subgroups #7007 oral

Hematologic Malignancies —Lymphoma and Chronic Lymphocytic Leukemia

Saturday 30 May 2026
5:12 – 5:24 PM CDT
Columvi (glofitamab) Fixed-duration glofitamab monotherapy in relapsed/refractory (R/R) mantle cell lymphoma (MCL) with/without prior Bruton’s tyrosine kinase inhibitor (BTKi) exposure: updated data after a 3.5-year follow-up #7006 oral

Hematologic Malignancies —Lymphoma and Chronic Lymphocytic Leukemia

Saturday 30 May 2026
5:00 – 5:12 PM CDT
Polivy Outcomes by LymphoMAP archetypes in untreated diffuse large B-cell lymphoma from the POLARIX trial #7017 rapid oral

Hematologic Malignancies —Lymphoma and Chronic Lymphocytic Leukemia

Friday 29 May 2026
2:12 – 2:18 PM CDT
Columvi, Lunsumio and Polivy Multivariable analyses (MVAs) of overall survival (OS) in the phase 3 SUNMO, STARGLO and POLARGO trials in relapsed/refractory large B-cell lymphoma (LBCL) #7093 poster

Hematologic Malignancies —Lymphoma and Chronic Lymphocytic Leukemia

Monday 01 June 2026
9:00 – 12:00 PM CDT
Lung cancer
Divarasib First-line (1L) divarasib plus pembrolizumab (pembro) in advanced or metastatic KRAS G12C+ non-small cell lung cancer (NSCLC): results from the Krascendo-170 study #8510 clinical science symposium

Lung Cancer — Non-Small Cell Metastatic

Saturday 30 May 2026
8:36 – 8:48 AM CDT
Tecentriq (atezolizumab) Transcriptomic analyses of molecular subsets and correlations with clinical outcomes from the phase 3 IMforte study of lurbinectedin (lurbi) + atezolizumab (atezo) maintenance treatment (Tx) in extensive-stage small-cell lung cancer (ES-SCLC) #8014 rapid oral

Lung Cancer — Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Sunday 31 May 2026
5:12 – 5:18 PM CDT
Tecentriq IMforte: Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of first-line maintenance (1Lm) treatment (Tx) with lurbinectedin (lurbi) + atezolizumab (atezo) vs atezo in extensive-stage small cell lung cancer (ES-SCLC) #8086 poster

Lung Cancer — Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Sunday 31 May 2026
9:00 – 12:00 PM CDT
Gastrointestinal cancer
Tecentriq IMbrave251: Final analysis of atezolizumab (atezo) plus lenvatinib (lenva) or sorafenib (sora) vs lenva or sora alone in locally advanced or metastatic hepatocellular carcinoma (LA/mHCC) previously treated with atezo and bevacizumab (bev) #4002 oral

Gastrointestinal Cancer —Gastroesophageal, Pancreatic, and Hepatobiliary

Monday 01 June 2026
10:09 – 10:21 AM CDT
Tecentriq Health-related quality of life (HRQOL) in the phase 3 trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III deficient DNA mismatch repair (dMMR) colon cancer (Alliance A021502, ATOMIC)* #3626 poster

Gastrointestinal Cancer —Colorectal and Anal

Saturday 30 May 2026
9:00 – 12:00 PM CDT
Bladder cancer
Tecentriq Patient-reported outcomes from IMvigor011: A phase 3 study of circulating tumor (ct)DNA-guided adjuvant atezolizumab vs placebo in muscle-invasive bladder cancer (MIBC) #4627 poster

Genitourinary Cancer — Kidney and Bladder

Sunday 31 May 2026
9:00 – 12:00 PM CDT
*Study led by the Alliance for Clinical Trials in Oncology and supported by Roche

(Press release, Hoffmann-La Roche, MAY 19, 2026, View Source [SID1234665845])